Meeting
2023 ASCO Quality Care Symposium
Comparative cost-effectiveness analysis of oral agents for advanced EGFR mutated and ALK-positive non-small cell lung cancer.
Authors
Dali Edwards
University of Rochester Medical Center - Wilmot Cancer Institute, Rochester, NY
Dali Edwards, Gahyun Gim, Kaitlin Kyi, Kushal Patel, Arpan Patel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Quality, Safety, and Implementation Science,Cost, Value, and Policy,Patient Experience,Survivorship
Sub Track
Cost and Cost-Effectiveness of Care
Citation
JCO Oncol Pract 19, 2023 (suppl 11; abstr 26)
DOI
10.1200/OP.2023.19.11_suppl.26
Abstract #
26
Poster Bd #
B9
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Correlation between overall response rate and progression-free survival/overall survival in comparative trials involving targeted therapies in molecularly enriched populations.
First Author: Benjamin J. Solomon
Poster
2018 ASCO Annual Meeting
Lorlatinib in patients (Pts) with previously treated ALK+ advanced non-small cell lung cancer (NSCLC): Updated efficacy and safety.
First Author: Benjamin Besse
Poster
2021 ASCO Annual Meeting
Modeling the cost-effectiveness of adjuvant osimertinib in resected EGFR-mutant non-small cell lung cancer patients.
First Author: Christopher Lemmon
Poster
2021 ASCO Annual Meeting
Outcomes of first, second, and third-generation anaplastic lymphoma kinase (ALK) inhibitors in non-small cell lung cancer brain metastases (NSCLCBM).
First Author: Vineeth Tatineni